Advancements in Discovering and Optimizing Novel Biotherapeutics
The COVID-19 pandemic resulted in a surge of activity by research groups working toward the rapid discovery and development of treatments and vaccines with attributes allowing global-scale production and deployment. With this as a foundation,
the PEGS Engineering Stream examines the state of the science in biologics R&D, including smarter and higher throughput screening methods, the increased role of AI and machine learning, novel constructs and the impacts of new understandings
of immunology on protein engineering. Plan to attend and learn why this has become the industry’s leading event in biotherapeutics.
Display of Biologics
Recommended Short Course:
SC3: Developability of Bispecific Antibodies: Formats and Applications
Instructor: Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
Jared Adolf-Bryfogle, PhD, Principal Scientist, Protein Design Laboratory, Institute for Protein Innovation
William F. DeGrado, PhD, Professor, Pharmaceutical Chemistry; Investigator, Cardiovascular Research Institute, University of California, San Francisco
Jane K. Osbourn, PhD, CSO, Alchemab Therapeutics Ltd.